Drug Profile
MBP 7595
Latest Information Update: 28 May 2007
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Briana Bio-Tech; Nonindustrial source
- Class Neuroprotectants; Peptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 12 Jan 2001 No-Development-Reported for Multiple sclerosis in Canada (IV)
- 09 Jul 1998 Phase-II clinical trials for Multiple sclerosis in Canada (IV)